Summary : AstraZeneca has failed in its bid to get US approval for its IL-5 inhibitor Fasenra as a treatment for chronic…
Tag:
Care
-
-
AstraZenecaDapagliflozin
NICE issues Draft Recommendation for AstraZeneca`s Forxiga (Dapagliflozin) to Treat Adults with Chronic Kidney Disease
by adminby adminAbstract: The National Institute for Health and Care Excellence (NICE) has issued an Appraisal Consultation Document (ACD) for AstraZeneca’s Forxiga (Dapagliflozin) within…
-
Iptacopan
Novartis Pharmaceuticals UK awarded an Innovation Passport for Investigational Oral Therapy Iptacopan (LNP023)
by adminby adminSUMMARY: Iptacopan has been awarded the Innovation Passport for the treatment of C3 glomerulopathy (C3G) and is currently being investigated in a…